Evaluating cost benefits of combination therapies for advanced melanoma

Ivar S Jensen, Emily Zacherle, Christopher M Blanchette, Jie Zhang, Wes Yin

Article Type

Original Research

Published

The model presented in this study was used to analyze the clinical and economic benefit of using combination therapies in advanced melanoma patients with the BRAF V600 mutation. The analysis suggests dabrafenib + trametinib therapy is associated with less patient time and lower costs relative to nivolumab + ipilimumab to gain similar progression-free survival and overall response rate benefits.

Read more

Clinical and cost outcomes from different hyaluronic acid treatments in patients with knee osteoarthritis: evidence from a US health plan claims database

Vinod Dasa, Mitch DeKoven, Kainan Sun, Allan Scott, Sooyeol Lim

Article Type

Original Research

Published

Intra-articular injection of hyaluronic acid (HA) for knee osteoarthritis (OA) effectively reduces pain and delays total knee replacement (TKR) surgery; however, little is known about relative differences in clinical and cost outcomes among different HA products. In this study, the authors conclude that analysis of administrative claims data provides real-world evidence that meaningful differences exist among some HA products in disease-specific cost and time to knee replacement surgery.

Read more

Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia

Michele Wilson, Benjamin Gutierrez, Steve J Offord, Christopher M Blanchette, Anna Eramo, Stephanie Earnshaw, Siddhesh A Kamat

Article Type

Original Research

Published

Schizophrenia is associated with high direct healthcare costs due to progression of disease and frequent occurrence of relapses. Aripiprazole once-monthly (AOM) has been shown to reduce total psychiatric hospitalizations among patients who switched from oral standard of care (SOC) therapy to AOM. In this paper the authors report the results of an economic model study to evaluate the psychiatric hospitalization-related medical costs and antipsychotic pharmacy costs during a 6-month period before and after initiation of AOM treatment.

Read more

An assessment of chemotherapy-induced nausea and vomiting direct costs in three EU countries

Marco Turini, Vittoria Piovesana, Pierfrancesco Ruffo, Claudio Ripellino, Nazarena Cataldo

Article Type

Original Research

Published

Inadequately treated, chemotherapy-induced nausea and vomiting (CINV) can lead to increased resource utilization and severely impair patients’ daily functioning and quality of life. The authors investigated the management of CINV episodes in three European health-care environments and estimate the direct costs associated with severe CINV episodes.

Read more

Progression of autosomal dominant kidney disease: measurement of the stage transitions of chronic kidney disease

Christopher M Blanchette, Caihua Liang, Deborah P Lubeck, Britt Newsome, Sandro Rossetti, Xiangmei Gu, Benjamin Gutierrez, Nancy D Lin

Article Type

Original Research

Published

Autosomal dominant polycystic kidney disease (ADPKD) is a progressive genetic disorder characterized by the development of numerous kidney cysts that result in kidney failure. The results of this study suggest that distribution of patients by age at transition to next stage may be useful for identification of ADPKD patients at risk of rapid progression.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.